Fluoroquinolone Resistance and gyrA and parC Mutations of Escherichia coli Isolated from Chicken

  • Lee Young-Ju (College of Veterinary Medicine, Kyungpook National University) ;
  • Cho Jae-Keun (Daegu Metropolitan City Research Institute of Health & Environment) ;
  • Kim Ki-Seuk (College of Veterinary Medicine, Kyungpook National University) ;
  • Tak Ryun-Bin (College of Veterinary Medicine, Kyungpook National University) ;
  • Kim Ae-Ran (National Veterinary Research and Quarantine Service, Ministry of Agriculture & Forestry) ;
  • Kim Jong-Wan (National Veterinary Research and Quarantine Service, Ministry of Agriculture & Forestry) ;
  • Im Suk-Kyoung (National Veterinary Research and Quarantine Service, Ministry of Agriculture & Forestry) ;
  • Kim Byoung-Han (National Veterinary Research and Quarantine Service, Ministry of Agriculture & Forestry)
  • Published : 2005.10.01

Abstract

Escherichia coli is a common inhabitant of the intestinal tracts of animals and humans. The intestines of animals also represent an ideal environment for the selection and transfer of antimicrobial resistance genes. The aim of this study was to investigate the resistance of E. coli isolated from chicken fecal samples to fluoroquinolones and to analyze the characterization of mutations in its gyrA and parC gene related resistance. One hundred and twenty-eight E. coil isolates showed a high resistance to ciprofloxacin (CIP; $60.2\%$), enrofloxacin (ENO; $73.4\%$) and norfloxacin (NOR; $60.2\%$). Missense mutation in gyrA was only found in the amino acid codons of Ser-83 or Asp-87. A high percentage of isolates ($60.2\%$) showed mutations at both amino acid codons. Missense mutation in parC was found in the amino acid codon of Ser-80 or Glu-84, and seven isolates showed mutations at both amino acid codons. Isolates with a single mutation in gyrA showed minimal inhibitory concentrations (MIC) for CIP (${\le}0.5\;to\;0.75{\mu}g/ml$), ENO (1 to $4{\mu}g/ml$) and NOR (0.75 to $4{\mu}g/ml$). These MIC were level compared to isolates with two mutations, one in gyrA and one in parC, and three mutations, one in gyrA and two in parC (CIP, ${\le}0.5\;to\;3{\mu}g/ml;\;ENO,\;2\;to\;32<{\mu}g/ml;\;NOR,\;1.5\;to\;6\;{\mu}g/ml$). However, the isolates with two mutation in gyrA regardless of whether there was a mutation in parC showed high MIC for the three fluoroquinolones (CIP, 0.75 to $32{\le}{\mu}g/ml;\;ENO,\;3\;to\;32{\le}{\mu}g/ml;\;NOR,\;3\;to\;32{\le}{\mu}g/ml$). Interestingly, although the E. coil used in this study was isolated from normal flora of chicken, not clinical specimens, a high percentage of isolates showed resistance to fluoroquinolones and possessed mutations at gyrA and parC associated with fluoroquinolone resistance.

Keywords

References

  1. Aarestrup, F.M., Y. Agerso, P. Gerner-Smidt, M. Madsen, and L.B. Jensen. 2000. Comparison of antimicrobial resistance phenotypes and resistance genes in Enterococcus faecalis and Enterococcus faecium from humans in the community, broilers, and pigs in Denmark. Diagn. Microbiol. Infect. Dis. 37, 127-37 https://doi.org/10.1016/S0732-8893(00)00130-9
  2. Amara, A., Z. Ziani, and K. Bouzoubaa. 1995. Antibiotic resistance of Escherichia coli strains isolated in Morocco from chickens with colibacillosis. Vet. Microbiol. 43, 325-330 https://doi.org/10.1016/0378-1135(94)00101-2
  3. Bass, L., C.A. Liebert, M.D. Lee, A.O. Summers, D.G. White, S.G. Thayer, and J.J. Maurer. 1999. Incidence and characterization of integrons, genetic elements mediating multiple-drug resistance, in avian Escherichia coli. Antimicrob. Agents Chemother. 43, 2925-2929
  4. Blanche, F., B. Cameron, F.X. Bernard, L. Maton, B. Manse, L., Ferrero, N. Ratet, C. Lecoq, A. Goniot, D. Bisch, and J. Crouzet. 1996. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob. Agents Chemother. 40, 2714-2720
  5. Bonten, M., E. Stobberingh, J. Philips, and A. Houben. 1990. High prevalence of antibiotic resistant Escherichia coli in faecal samples of students in the south-east of The Netherlands. J. Antimicrob. Chemother. 26, 585-592 https://doi.org/10.1093/jac/26.4.585
  6. Cambau, F. and L. Gutmann. 1993. Mechanisms of resistance to quionolones. Drugs 45, 15-23
  7. Chin, S.C., N. Abdullah, T.W. Siang, and H.Y. Wan. 2005. Plasmid profiling and curing of Lactobacillus strains isolated from the gastrointestinal tract of chicken. J. Microbiol 43, 251-256
  8. Everett, M.J., Y.F. Jin, V. Ricci, and L.J. Piddock. 1996. Contribution of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob. Agents Chemother. 40, 2380-2386
  9. Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13, 641-653 https://doi.org/10.1111/j.1365-2958.1994.tb00458.x
  10. Han, H.S., H.Y. Nam, Y.J. Koh, J.S. Hur, and J.S. Jung. 2003. Molecular bases of high-level streptomycin resistance in Pseudomonas marginalis and Pseudomonas syringae pv. actinidiae. J. Microbiol. 41, 16-21
  11. Han, M.W. and T.H. Wood. 1969. Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies. J. Bacteriol. 99, 238-24
  12. Heisig, P. 1996. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 40, 879-885
  13. Heisig, P., H. Schedletzdy, and H. Falkenstein-Paul. 1993. Mutations in the gyrA gene of a high-level fluoroquinolone-resistant clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 37, 696-701 https://doi.org/10.1128/AAC.37.4.696
  14. Hooper, D.C. 1995. Quinolone mode of action. Drugs. 49(Suppl. 2), 10-15 https://doi.org/10.2165/00003495-199500492-00004
  15. Hoshino, K., A. Kitamura, I. Morrissey, K. Sato, J. Kato, and H. Ikeda. 1994. Inhibition of quinolones against topoisomerase IV from Escherichia coli and comparison with the inhibitory potency against DNA gyrase. Antimicrob. Agents Chemother. 38, 2623-2627 https://doi.org/10.1128/AAC.38.11.2623
  16. Kato, J., H. Suzuki, and H. Ikeda. 1992. Purification and characterization of DNA topoisomerase IV in Eshcherichia coli. J. Biol. Chem. 267, 25676-25684
  17. Khodursky, A.B. and Cozzarelli, N.R. 1998. The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J. Biol. Chem. 274, 27668-27677
  18. Kumagai, Y., J.I. Kato, K. Hoshino, T. Akasaka, K. Sato, and H. Ikeda. 1996. Quinolone-resistant mutants of Escherichia coli DNA topoisomerase IV parC gene. Antimicrob. Agents Chemother. 40, 710-714
  19. Lagatolla, C., L. Dolzani, E. Tonin, A. Lavenia, M.D. Michele, T. Tommasini, and C. Monti-Bragadin. 1996. PCR ribotyping for characterizing Salmonella isolates of different serotypes. J. Clin. Microbiol. 34, 2440-2443
  20. Lee, Y.J., K.S. Kim, J.H. Kim, and R.B. Tak. 2004. Salmonella gallinarum gyrA mutations associated with fluoroquinolone resistance. Avian Pathol. 33, 251-257 https://doi.org/10.1080/0301945042000195759
  21. Lee, Y.J., K.S. Kim, Y.K. Kwon, and R.B. Tak. 2003. Biochemical characteristics and antimicrobials susceptibility of Salmonella gallinarum isolated in Korea. J. Vet. Sci. 4, 161-166
  22. Murray, B.E. 1990. The life and times of the Enterococcus. Clin. Microbiol. Rev. 3, 46-65
  23. NCCLS. 2000. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard-fifth edition. M31-A
  24. Oram, M. and L.M. Fisher. 1991. 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob. Agents Chemother. 35, 387-389 https://doi.org/10.1128/AAC.35.2.387
  25. Peng, H. and K. Marians. 1993. Escherichia coli topoisomerase IV: purification, characterization, subunit structure, and subunit interactions. J. Biol. Chem. 268, 24481-24490
  26. Pinheiro, E.T., B.P.F.A. Gomes, D.B. Drucker, A.A. Zaia, C.C.R. Ferraz, and F.J. Souza-Filho. 2004. Antimicrobial susceptibility of Enterococcus faecalis isolated from canals of root filled teeth with periapical lesions. Int. Endo. J. 37, 756-763 https://doi.org/10.1111/j.1365-2591.2004.00865.x
  27. Prescott, J.F. and Baggot, J.D. 1993. Fluoroquinolones. p. 252-262. In Antimicrobial therapy in veterinary medicine, 2nd ed, Iowa State University Press, Ames, Iowa
  28. Quabdesselam, S., D.C. Hopper, J. Tankovic, and C.J. Soussy. 1995. Detection of gyrA and gyrB mutations in quinoloneresistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. Antimicrob. Agents Chemother. 39, 1667-1670 https://doi.org/10.1128/AAC.39.8.1667
  29. Soussy, C.J., J.S. Wolfson, E.Y. Ng, and D.C. Hooper. 1993. Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus. Antimicrob. Agents Chemother. 37, 2588-2592 https://doi.org/10.1128/AAC.37.12.2588
  30. Yoshida, H., M. Bogaki, M. Nakamura, and S. Nakamura. 1990. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 34, 1271-1272 https://doi.org/10.1128/AAC.34.6.1271